Quantifying the risk of hypocalcemia in individuals treated with cabozantinib. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback